2149 related articles for article (PubMed ID: 32907565)
41. How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?
Euvrard J; Schulz T; Hilderbrand K; Bosland M; Osler M; Boulle A; Davies MA
S Afr Med J; 2019 Feb; 109(3):174-177. PubMed ID: 30834874
[TBL] [Abstract][Full Text] [Related]
42. Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012.
Jean K; Puren A; Cutler E; Singh B; Bouscaillou J; Rain-Taljaard R; Taljaard D; Gouws E; Lissouba P; Lewis DA; Peytavin G; Auvert B
AIDS; 2016 Aug; 30(13):2107-16. PubMed ID: 27163707
[TBL] [Abstract][Full Text] [Related]
43. HIV viral load non-suppression and associated factors among pregnant and postpartum women in rural northeastern South Africa: a cross-sectional survey.
Ngandu NK; Lombard CJ; Mbira TE; Puren A; Waitt C; Prendergast AJ; Tylleskär T; Van de Perre P; Goga AE
BMJ Open; 2022 Mar; 12(3):e058347. PubMed ID: 35273061
[TBL] [Abstract][Full Text] [Related]
44. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial.
Thomas R; Burger R; Harper A; Kanema S; Mwenge L; Vanqa N; Bell-Mandla N; Smith PC; Floyd S; Bock P; Ayles H; Beyers N; Donnell D; Fidler S; Hayes R; Hauck K;
Lancet Glob Health; 2017 Nov; 5(11):e1133-e1141. PubMed ID: 28964756
[TBL] [Abstract][Full Text] [Related]
45. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.
de Oliveira T; Kharsany AB; Gräf T; Cawood C; Khanyile D; Grobler A; Puren A; Madurai S; Baxter C; Karim QA; Karim SS
Lancet HIV; 2017 Jan; 4(1):e41-e50. PubMed ID: 27914874
[TBL] [Abstract][Full Text] [Related]
46. Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial.
Wirth KE; Gaolathe T; Pretorius Holme M; Mmalane M; Kadima E; Chakalisa U; Manyake K; Matildah Mbikiwa A; Simon SV; Letlhogile R; Mukokomani K; van Widenfelt E; Moyo S; Bennett K; Leidner J; Powis KM; Lebelonyane R; Alwano MG; Jarvis J; Dryden-Peterson SL; Kgathi C; Moore J; Bachanas P; Raizes E; Abrams W; Block L; Sento B; Novitsky V; El-Halabi S; Marukutira T; Mills LA; Sexton C; Pals S; Shapiro RL; Wang R; Lei Q; DeGruttola V; Makhema J; Essex M; Lockman S; Tchetgen Tchetgen EJ
Lancet HIV; 2020 Jun; 7(6):e422-e433. PubMed ID: 32504575
[TBL] [Abstract][Full Text] [Related]
47. Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d'Ivoire: Insights from mathematical modeling.
Maheu-Giroux M; Vesga JF; Diabaté S; Alary M; Baral S; Diouf D; Abo K; Boily MC
PLoS Med; 2017 Jun; 14(6):e1002321. PubMed ID: 28617810
[TBL] [Abstract][Full Text] [Related]
48. Trends and determinants of ever having tested for HIV among youth and adults in South Africa from 2005-2017: Results from four repeated cross-sectional nationally representative household-based HIV prevalence, incidence, and behaviour surveys.
Jooste S; Mabaso M; Taylor M; North A; Tadokera R; Simbayi L
PLoS One; 2020; 15(5):e0232883. PubMed ID: 32407342
[TBL] [Abstract][Full Text] [Related]
49. The continuum of HIV care in South Africa: implications for achieving the second and third UNAIDS 90-90-90 targets.
Takuva S; Brown AE; Pillay Y; Delpech V; Puren AJ
AIDS; 2017 Feb; 31(4):545-552. PubMed ID: 28121668
[TBL] [Abstract][Full Text] [Related]
50. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
51. Awareness of HIV-positive status and linkage to treatment prior to pregnancy in the "test and treat" era: A national antenatal sentinel survey, 2017, South Africa.
Woldesenbet S; Kufa T; Cheyip M; Ayalew K; Lombard C; Manda S; Nadol P; Barron P; Chirombo B; Igumbor E; Pillay Y; Puren A
PLoS One; 2020; 15(3):e0229874. PubMed ID: 32168356
[TBL] [Abstract][Full Text] [Related]
52. Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey.
Cherutich P; Kim AA; Kellogg TA; Sherr K; Waruru A; De Cock KM; Rutherford GW
PLoS One; 2016; 11(5):e0154318. PubMed ID: 27192052
[TBL] [Abstract][Full Text] [Related]
53. Progress toward HIV epidemic control in Lesotho.
Thin K; Frederix K; McCracken S; Letsie M; Low A; Patel H; Parekh B; Motsoane T; Ahmed N; Justman J; Callaghan L; Tembo S; Schwitters A
AIDS; 2019 Dec; 33(15):2393-2401. PubMed ID: 31764104
[TBL] [Abstract][Full Text] [Related]
54. Study protocol: Strengthening understanding of effective adherence strategies for first-line and second-line antiretroviral therapy (ART) in selected rural and urban communities in South Africa.
Gumede SB; de Wit JBF; Venter WDF; Lalla-Edward ST
PLoS One; 2021; 16(12):e0261107. PubMed ID: 34932588
[TBL] [Abstract][Full Text] [Related]
55. HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis.
Stannah J; Dale E; Elmes J; Staunton R; Beyrer C; Mitchell KM; Boily MC
Lancet HIV; 2019 Nov; 6(11):e769-e787. PubMed ID: 31601542
[TBL] [Abstract][Full Text] [Related]
56. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
[TBL] [Abstract][Full Text] [Related]
57. Progress Toward the 90-90-90 HIV Targets in Zimbabwe and Identifying Those Left Behind.
Hakim AJ; Tippett Barr BA; Kinchen S; Musuka G; Manjengwa J; Munyati S; Gwanzura L; Mugurungi O; Ncube G; Saito S; Parekh BS; Patel H; Duong YT; Gonese E; Sleeman K; Ruangtragool L; Justman J; Herman-Roloff A; Radin E
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):272-281. PubMed ID: 34321414
[TBL] [Abstract][Full Text] [Related]
58. Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia.
Floyd S; Ayles H; Schaap A; Shanaube K; MacLeod D; Phiri M; Griffith S; Bock P; Beyers N; Fidler S; Hayes R;
PLoS One; 2018; 13(8):e0197904. PubMed ID: 30096139
[TBL] [Abstract][Full Text] [Related]
59. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa.
Joseph Davey D; Abrahams Z; Feinberg M; Prins M; Serrao C; Medeossi B; Darkoh E
Int J STD AIDS; 2018 May; 29(6):603-610. PubMed ID: 29334886
[TBL] [Abstract][Full Text] [Related]
60. 90-90-90 cascade analysis on reported CLHIV infected by mother-to-child transmission in Guangxi, China: a modeling study.
Wang G; Lu C; Qin S; Wei W; Lai J; Jiang J; Liang B; Zhou O; Han J; Yang Y; Ye L; Liang H; Ning C
Sci Rep; 2020 Mar; 10(1):5295. PubMed ID: 32210333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
